
Cowles family plans to donate The Spokesman-Review to local nonprofit
The plan calls for Publisher Stacey Cowles and his family's Cowles Co. to transfer ownership of the newspaper and award a $2 million matching grant to the nonprofit, called the Comma community journalism lab, which was founded by current Spokesman-Review Executive Editor Rob Curley.
"It's been a great venture for 132 years, but if you had the chance to extend its viability, as people know and love it, why would you not do that?" Cowles said. He is among the fourth generation of the Cowles family to publish the city's daily paper.
Cowles will stay involved with the newspaper as a member of Comma's board of directors. Curley also will serve on the board of 11 and lead the nonprofit as founder and president.
"We firmly believe this is a great plan and the community and Comma have the resources to carry it off," Cowles said. "Of course, we're going to be helping to whatever extent we can. We're super excited to see this go."
The change will not affect how readers get their newspaper, Curley said. The Spokesman-Review will continue to publish as it does currently: six days a week in print and always online behind a paywall, though stories reported and written by reporters whose positions are funded at least partially by outside grants will remain free.
When the nonprofit reaches its fundraising goal and takes over the newspaper — potentially by mid-summer — readers will be offered subscription plans with different ways to engage with the newspaper content and process.
"We believe a community should own its narrative, and the local newspaper must be created with and for its communities," Curley said, "especially in today's climate, that starts with putting power back into the hands of readers and citizens."
The agreement includes a stipulation that current employees of The Spokesman-Review keep at least the same pay and benefits, Cowles said. He noted there are some details that needs to be ironed out as Comma works to raise the initial $2 million to trigger the Cowles' $2 million match.
"There won't be any positions cut as a result of this move, per se," Cowles said. "But we're always looking for efficiencies, so we'll have retirements, we'll have restructuring, but that won't be contingent on the nonprofit."
Comma's business model, developed with help and guidance from nonprofit consulting firm the Bridgespan Group, calls for donations from individuals and major local companies and institutions such as Avista Corp. or Gonzaga, for example.
Curley said what sets it apart from similar ventures is a hybrid revenue stream called the "Spokane model." The newspaper would shift from a reliance on advertising and subscription revenue under a for-profit structure to a hybrid model that continues gathering these forms of revenue with added philanthropy.
Conversations around this model have been underway for years as Curley weaved elements of philanthropy through his eight years as editor.
He started fundraising efforts through the Community Journalism and Civic Engagement Fund, which includes Northwest Passages book club events and collecting corporate sponsors for coverage, such as the annual Difference Makers series.
Last year, the newspaper collected about $300,000 from nonprofit ventures, Cowles said. Now it's going a step further under a model that could bring in between $800,000 to $3 million each year.
It's an effort to move from "a community newspaper" to "the community's newspaper," Curley said.
Cowles said the newspaper's focus on a community-style of journalism has better resonated with readers, who felt they were more represented in the stories on the front page. Cowles described the style as "the way of the future."
"(Curley's) brand of community journalism is really what has driven this and the response he got when in the first two months, we went from 10 complaint letters to 200 love letters," Cowles said. "What more do you need to say, 'Well, this looks like the right formula.' Then the question is, 'Well, how can we sustain it over a long, long period?'"
The added revenue stream is necessary to the function of the newspaper as readers know it today, Cowles said. The Spokesman-Review is not immune to woes of the newspaper industry struggling with profitability and survivability.
"We're losing two newspapers a week across the country. And we have been for three years now. The industry is in a crisis; there's no question," Cowles said. "That's why you've got people like us coming up with solutions like this because of necessity. If we don't figure something out, we're going to end up on the junk heap."
It's the societal shift toward digitization that has made it difficult for most newspapers.
The Spokesman-Review is generating 70% less revenue than it was in 2007, largely due to the shift from print to digital advertising, Cowles said. Revenue from subscriptions isn't enough to compensate for this drag, even with hikes in subscription fees and value-added pricing for delivery that grew subscription revenue over the past five years, Cowles said, but even that is now leveling off.
"How do we fill the gap if we're going to stay at some semblance of the size newsroom we have," Cowles said.
Philanthropy, future Comma executives hope, is how to fill the gap, and for more than just The Spokesman-Review.
"It's a way for people that are subscribers to grow into being supportive philanthropists within the community," said Comma principal and board member Scott de Rozic, who has worked with Curley to make Comma ready for the transfer.
Once finalized, Comma's business plans, financial models, legal documents and other details will be open source, available for the reference of other newspapers, which de Rozic hopes could help keep other publications afloat.
"We also want to deeply inform through sharing and an open source model, all of our learnings here with the rest of the country," de Rozic said. "Because geographically we know we can't fix all the problems in the country, but we want the lessons that we learned and invested money in to be available, freely available, for the rest of the industry."
The decision to transfer Cowles' family's long-standing asset wasn't easy for him or his family, who all weighed in on this deal.
In his sixth-floor office of the iconic Spokesman-Review Tower at the corner at southeast corner of Monroe Street and Riverside Avenue, black-and-white photos of his family offer reassurance.
"I think all my ancestors would agree this is a good move," Cowles said.
Elena Perry's work is funded in part by members of the Spokane community via the Community Journalism and Civic Engagement Fund. This story can be republished by other organizations for free under a Creative Commons license. For more information on this, please contact our newspaper's managing editor.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


San Francisco Chronicle
29 minutes ago
- San Francisco Chronicle
A massive office tower could replace this struggling downtown S.F. university campus
A massive skyscraper could rise at the downtown San Francisco site of the financially troubled Golden Gate University, according to an application filed with the city's Planning Department last week. The application proposes two redevelopment options for the 236,000-square-foot law school's flagship campus, which sits in the heart of the Financial District at 536 Mission St.: either a 700-foot tower featuring roughly 1.3 million square feet of office space or a slightly smaller, 650-foot tower that would provide just over 550,000 square feet of new offices alongside 370 new homes. The Chronicle reported previously that Texas-based developer Lincoln Properties has an option to purchase the downtown campus, and also provided a $21.9 million loan to the university, helping to pay off existing debt on the property. Public records show that the campus' sale has yet to close. The application for the property's redevelopment was filed by an attorney representing Royal MP Transbay LLC, a limited liability company registered to Lincoln Property. The developer told the Chronicle previously that it has partnered with New York-based real estate firm McCourt Partners on the pending bid to buy the campus. McCourt Partners has experience in office, hotel and residential construction. San Francisco-based architecture firm SOM is listed as the architect for plans filed with the city for the redevelopment project. A university spokesperson did not respond to an inquiry from the Chronicle about the redevelopment application on Monday. Lincoln Property and McCourt Partners could not immediately be reached for comment. The San Francisco Business Times first reported on the proposal Monday. Should the developers win approval for the mixed-use project proposed at the campus property, the plan would be to construct 160 one-bedroom units, 100 two-bedroom units and 110 studios, per the application. Both the office and the mixed-use tower variants would feature 46 stories. Both plans would require the demolition of the existing, seven-story campus. The university redevelopment plan is the second proposal for a massive downtown skyscraper to land before city planners in recent months: Last month, developer Hines filed plans for a slender 1,225-foot tower to replace an office building at 77 Beale St. That tower would be more than 150 feet taller than Salesforce Tower, which at 1,070 feet is San Francisco's tallest building and was co-developed by Hines. The university campus poised for redevelopment by Lincoln Property sits a block from Salesforce Tower and the Transbay transit center — a regional transportation center and mixed-use development that is also managed by the developer. The new office development proposals come as the city's beleaguered office market is starting to show signs of life, primarily due to artificial intelligence startups driving new leasing demand. And yet, San Francisco continues to wrangle with significant commercial vacancy in its downtown core, where roughly one-third of the city's office space sits vacant, and many large redevelopment efforts that have been approved in downtown and other parts of the city remain on hold. Whether Golden Gate University's future will include the 536 Mission property is not clear — real estate insiders have told the Chronicle that the school could remain involved in the redevelopment through a lease back deal. The university is currently in the midst of searching for a new president, and expects to announce its selection in the fall. In the past, the school's leadership has stated that Golden Gate University will maintain a presence in downtown San Francisco — a sentiment that acting president Bruce Magid repeated in a statement to the Chronicle on Monday


Business of Fashion
33 minutes ago
- Business of Fashion
GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts
US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. US list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. ADVERTISEMENT The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4 percent after 72 weeks in a trial. That compares with weight loss of 15 percent for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21 percent. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is 'probably going to come on par with the current drugs today or slightly lower,' Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. Growing Cash Pay US doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40 percent of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce US prices. Novo declined to comment on pricing, pointing to Aug. 6 comments by David Moore, its US operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. ADVERTISEMENT Manufacturing Volume A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the US market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. 'It's all about scale and pricing,' said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. 'Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy,' Andersen added. By Maggie Fick and Bhanvi Satija; Editors: Caroline Humer and Will Dunham Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis.


Los Angeles Times
an hour ago
- Los Angeles Times
Orbital Operations Raises $8.8-Million Seed Round
Long Beach-based Orbital Operations raised an $8.8-million seed round led by Initialized Capital to build high-thrust orbital vehicles. The company was founded in 2023 by former Relativity Space engineers Benjamin Schleuniger and Ross Doherty, who recently participated in Y Combinator's accelerator program. It is developing Astraeus, a high-thrust, cryogenic space vehicle that can stay in orbit for years. The company is focused on national defense and intends for the U.S. Space Force to utilize its space vehicle as a third-stage rocket that can loiter indefinitely for interception and space domain awareness. Astraeus will be powered by a proprietary 10,000 lb-thrust engine, capable of delivering 10 kilometers per second of delta-v, which is enough to wait in low Earth orbit, then sprint to a target when needed. Fuel components, liquid hydrogen and oxygen boil off in space, which can cut missions short. The company plans to develop an active cooling system with heat exchangers and turbomachinery to keep propellants stable. While the tech could serve commercial uses, it is developing technology first for counterspace defense. With the funding, it will develop an engine test stand and a ground-based demo of the cooling system, aiming to prove long-term propellant storage by year's end. Information for this article was sourced from Orbital Operations.